---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-069440"
form_type: "8-K"
ticker: "OBIO"
cik: "0001814114"
company_name: "Orchestra BioMed Holdings, Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:11:26.037233+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Orchestra BioMed appoints Andrew Taylor as CFO, Bill Little as EVP Corp Dev

## Summary
- Michael Kaswan stepped down as CFO effective June 6, 2023; will consult at $36,180/month for up to 6 months.
- Andrew Taylor appointed CFO; formerly CFO of Motus GI (MOTS), base salary $395,000, target bonus 50% of salary, initial equity grant of up to 278,502 RSUs or 417,544 options.
- Bill Little appointed EVP of Corporate Development and Strategy; previously COO of Neovasc until its acquisition by Shockwave Medical.
- Kaswan's consulting agreement includes $108,540 lump sum and additional three months' service vesting for equity.
- Little to focus on strategic collaborations; partnerships with Medtronic and Terumo continue.

## SEC filing metadata
- accession: 0001104659-23-069440
- form_type: 8-K
- ticker: OBIO
- cik: 0001814114
- company_name: Orchestra BioMed Holdings, Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1814114/000110465923069440/0001104659-23-069440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1814114/000110465923069440/tm2318000d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-069440
- JSON: https://secwatch.observer/filing/0001104659-23-069440.json
- Plain text: https://secwatch.observer/filing/0001104659-23-069440.txt

## Key facts
- Executive change
  Andrew Taylor was appointed as Chief Financial Officer at Orchestra BioMed Holdings, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: the board of directors of the Company (the “Board”) appointed Mr. Andrew Taylor, age 52, as Chief Financial Officer of the Company to succeed Mr. Kaswan, effective as of the Separation Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1814114/000110465923069440/0001104659-23-069440-index.htm
- Executive change
  Michael Kaswan departed as Chief Financial Officer at Orchestra BioMed Holdings, Inc..
  - Action: stepped down
  - Role: Chief Financial Officer
  source text: Mr. Michael Kaswan, the Company’s Chief Financial Officer, mutually agreed to terms pursuant to which Mr. Kaswan will step down as the Company’s Chief Financial Officer and separate from employment effective as of June 6, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1814114/000110465923069440/0001104659-23-069440-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.